NUMA1 and in situ carcinoma: Their findings revealed that the co-presence of positive urine cytology and NMP22 indicated a significantly elevated risk (20-fold) of G3/CIS tumors, demonstrating the potential of urinary biomarkers to provide valuable insights into tumor behavior for better-informed medical decisions.